320337-48-2 Usage
Description
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline is a complex organic compound with a unique molecular structure. It is characterized by its chloro and fluoro substitutions on the benzyloxy phenyl ring, as well as the hydroxymethylfuran-2-yl group attached to the quinazoline core. 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline has potential applications in various fields due to its structural properties and functional groups.
Uses
Used in Pharmaceutical Industry:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline is used as a potential therapeutic agent for the treatment of various types of cancer. Its unique molecular structure allows it to target specific cellular pathways and receptors, making it a promising candidate for the development of targeted cancer therapies.
Used in Drug Delivery Systems:
In the field of drug delivery, 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline can be employed as a component in the design of novel drug delivery systems. Its structural properties may enable the development of targeted drug carriers, improving the bioavailability and therapeutic efficacy of various pharmaceutical compounds.
Used in Chemical Research:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline can also be utilized in chemical research as a starting material or intermediate for the synthesis of other complex organic molecules. Its unique functional groups and structural features make it a valuable tool for exploring new chemical reactions and developing innovative synthetic strategies.
Used in Material Science:
4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-hydroxymethylfuran-2-yl)quinazoline may find applications in the field of material science, particularly in the development of new materials with specific properties. Its structural features could be exploited to create materials with tailored characteristics, such as improved stability, enhanced reactivity, or unique optical properties.
Check Digit Verification of cas no
The CAS Registry Mumber 320337-48-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,2,0,3,3 and 7 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 320337-48:
(8*3)+(7*2)+(6*0)+(5*3)+(4*3)+(3*7)+(2*4)+(1*8)=102
102 % 10 = 2
So 320337-48-2 is a valid CAS Registry Number.
320337-48-2Relevant articles and documents
Synthesis and in vitro biological evaluation of novel quinazoline derivatives
Zhang, Yaling,Zhang, Ying,Liu, Juan,Chen, Li,Zhao, Lijun,Li, Baolin,Wang, Wei
supporting information, p. 1584 - 1587 (2017/03/16)
A series of novel 4-arylamino-6-(5-substituted furan-2-yl)quinazoline derivatives were designed, synthesized and evaluated on biological activities in vitro. Compound 2a, 3a and 3c exhibited highly anti-proliferation activities on all tested tumor cell lines including SW480, A549, A431 and NCI-H1975 cells. Especially, compound 2a not only exhibited strong anti-proliferation activities against the tumor cell lines which expressed wild type or mutant EGFRL858R/T790M, but also showed the most potent inhibitory activity toward wild type EGFR (IC50?=?5.06?nM). The result of docking with EGFR suggested the binding mode of 2a was similar to that of lapatinib. While Western-blot analyses showed 2a obviously inhibited the activation of EGFR, Akt and Erk1/2 in lung cancer cells at indicated concentration. It is believed that this work would be very useful for developing a new series of TKIs targeting EGFR.
Quinazoline Derivatives, Preparation Methods and Uses Thereof
-
Page/Page column 11, (2009/01/20)
The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.
Anilinoquinazolines as protein tyrosine kinase inhibitors
-
Page/Page column 72; 87, (2008/06/13)
Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
